Naamit Sher
Keine laufenden Positionen mehr
Profil
Naamit Sher worked as the VP of Drug Development & Regulatory Affairs at Vascular Biogenics Ltd.
She was also the Director of Quality Control & Quality Assurance at Interpharm Laboratories Ltd.
and the Head of QC Laboratories at Teva Pharmaceutical Industries Ltd.
Additionally, she held the title of Principal at Teva North America.
Dr. Sher received her undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Ehemalige bekannte Positionen von Naamit Sher
| Unternehmen | Position | Ende |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01.01.2006 |
| Teva North America | Corporate Officer/Principal | - |
Interpharm Laboratories Ltd.
 Interpharm Laboratories Ltd. BiotechnologyHealth Technology Part of Merck KGaA, Interpharm Laboratories Ltd. is an Israeli company that develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases. The company is based in Rehovot, Israel. The company was founded by Israel Makov. | Corporate Officer/Principal | - |
| NOTABLE LABS, LTD. | General Counsel | - |
Ausbildung von Naamit Sher
| The Hebrew University of Jerusalem | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
| Teva North America | |
Interpharm Laboratories Ltd.
Interpharm Laboratories Ltd. BiotechnologyHealth Technology Part of Merck KGaA, Interpharm Laboratories Ltd. is an Israeli company that develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases. The company is based in Rehovot, Israel. The company was founded by Israel Makov. | Health Technology |
